Introduction {#Sec1}
============

As the hallmark of cancers, genome instability participates in the initiation and progression of cancers by inducing the generation of mutations and neoantigens \[[@CR1]--[@CR4]\]. Genome instability is closely related with inadequate repertoire of DNA repair pathways \[[@CR5], [@CR6]\]. For sustaining cell viability, cancer cells highly depend on some specific DNA damage repair pathways to control DNA damage events in a low level \[[@CR7]\]. Thus, these essential repair pathways are ideal targets for cancer treatment \[[@CR8], [@CR9]\].

In normal cells, DNA damages could be detected and repaired by DNA single-strand break (SSB) repair pathways or double-strand break (DSB) repair pathways \[[@CR10], [@CR11]\]. SSB repair pathways include mismatch repair (MMR), nucleotide excision repair (NER), and base excision repair (BER), while DSB repair pathways include homologous recombination (HR) and nonhomologous end joining (NHEJ) \[[@CR12]--[@CR14]\]. Compared with SSB, DSB is a more cytotoxic form of DNA damage \[[@CR15]\]. When replicated sister chromatid and key molecules in HR pathway such as BRCA1/2 are available, cell could faithfully repair DSB damages by HR \[[@CR16]\]. In the absence of template DNA or intact HR pathway, NHEJ pathway is adopted to repair DSB damages \[[@CR17]\]. However, NHEJ is a rapid as well as error-prone repair pathway by direct ligation \[[@CR18]\]. Due to the low-fidelity, NHEJ often produces plenty of chromosomal rearrangements and these unsustainable DNA damages are harmful to cell viability \[[@CR19]\]. For HR deficient tumor cells, intact SSB repair pathways is the vital prerequisites for cell survival \[[@CR20]\].

Based on synthetic lethality theory, simultaneously blocking SSB repair and HR repair pathways could severely inhibit cell survival \[[@CR20]\]. Therefore, as the core component of SSB, Poly (ADP-ribose) polymerase (PARP) is an ideal treatment target for HR deficient cancers \[[@CR21]\]. Initially, it was found that PARP inhibitor (PARPi) could effectively kill BRCA1/2 mutated tumor cells \[[@CR22], [@CR23]\]. Later, it was noticed that some non-BRCA1/2 mutated HR deficient tumors were sensitive to PARPi treatment as well \[[@CR24]\]. PARPi not only inhibits the catalytic activity of PARP, but also traps PARP on damaged DNA site \[[@CR25], [@CR26]\]. The persistent PARP-DNA chain complex leads to the stalling of DNA replication fork \[[@CR27]\]. Then, DNA replication fork collapses and generates DSB \[[@CR27]\]. Due to the difference of HR status between normal cells and cancer cells, PARPi-induced DSB could be repaired by HR pathway in normal cells while the DSB is repaired by NHEJ pathway in cancer cells \[[@CR27]\]. As a result, tumor cells harboring HR deficiency are more sensitive to PARPi therapy than normal cells (e.g. over 1000 times in BRCA1/2 mutated tumor cells) \[[@CR27]\]. In theory, a wider group of patients could benefit from PARPi treatment beyond germline BRCA1/2 mutated (gBRCAm) patients.

The structure and function of PARP {#Sec2}
==================================

Poly (ADP-ribose) polymerase (PARP) family of enzymes participate in various cellular processes via covalently adding poly (ADP-ribose) chains onto target molecules (also termed as PARylation) \[[@CR28]\]. Among all proteins belonging to PARP family, PARP1 is mostly correlated with DNA damage repair which generates nearly 90% of poly (ADP-ribose) chains after DNA damage event \[[@CR29]\]. There are six main domains of PARP1 which include three zinc finger-related domains (DNA binding domains), one BRCA1 C-terminus domain (auto-modification domain), one tryptophan-/glycine-/arginine-rich domain (WGR domain), and one catalytic domain (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR30]\]. The catalytic domain of PARP1 consists of two subdomains: one helical domain (HD) and one ADP-ribosyltransferase catalytic domain (ART) \[[@CR30]\]. In the non-DNA binding status, HD inhibits the binding between PARP1 and its cofactor β-nicotinamide adenine dinucleotide (β-NAD) in ART \[[@CR30], [@CR31]\]. Once DNA SSB emerges, PARP1 could recognize and interact with SSB by its zinc finger-related domains \[[@CR32]\]. After PARP1 binding to damaged DNA chains, the auto-inhibitory function of HD is abrogated and the catalytic function of ART is activated \[[@CR32]\]. This catalytic activity leads to the generation of PAR chains on a series of target proteins which promotes the recruitment of DNA repair effectors and chromatin remodeling \[[@CR33]\]. Then the auto-PARylation on PARP1 protein causes the dissociation of PARP1 from DNA chains and restores the auto-inhibitory status of PARP1 \[[@CR32]\].Fig. 1PARP and PARPis. **a** The structure schematic of PARP molecule. There are six main domains of PARP1 which include three zinc finger-related domains (DNA binding domains), one BRCA1 C-terminus domain (auto-modification domain), one tryptophan-/glycine-/arginine-rich domain (WGR domain), and one catalytic domain. The catalytic domain of PARP1 consists of two subdomains: one helical domain (HD) and one ADP-ribosyltransferase catalytic domain (ART). **b** Three-dimensional structure of PARP1 molecule. The above structures were presented by PyMOL Molecular Graphics System (PDB ID: 5XST \[[@CR104]\]). **c** The chemistry structural formula of PARPis. **d** The function of PARP and synthetic lethal interaction between PARP and HR. Once DNA SSB emerges, PARP1 could recognizes and interacts with SSB by its zinc finger-related domains. After PARP1 binding to damaged DNA chains, the auto-inhibitory function of HD is abrogated and the catalytic function of ART is activated. This catalytic activity leads to the generation of PAR chains on a series of target proteins which promotes the recruitment of DNA repair effectors and chromatin remodeling. Then the auto-PARylation on PARP1 protein causes the dissociation of PARP1 from DNA chains and restores the auto-inhibitory status of PARP1. For HR deficient tumor cells, active SSB repair pathways is the vital prerequisites for cell survival. After PARPi treatment, NHEJ is used to repair PARPi-introduced DSB. However, NHEJ is a rapid as well as error-prone repair pathway by direct ligation. Due to the low-fidelity, NHEJ often produces plenty of chromosomal rearrangements and these unsustainable DNA damages are harmful to cell viability

Clinical development of PARP inhibitors {#Sec3}
=======================================

Some nicotinamide analogs could competitively inhibit the binding of β-NAD to ART and enhance the cytotoxicity of DNA damaging agents \[[@CR34]\]. Based on the structure of nicotinamide analogs, at least four PARPis are developed into clinical application including Olaparib, Rucaparib, Niraparib, and Talazoparib (Table [1](#Tab1){ref-type="table"}) \[[@CR35]--[@CR38]\]. All PARPis have the capability to suppress the catalytic activity of ART \[[@CR39]\]. However, PARPi-mediated inhibition of catalytic activity could not completely explain the phenomenon that the PARPi-mediated tumor-killing effect is greater than PARP depletion \[[@CR26]\]. Recent studies indicated that the cytotoxicity of PARPis are more relevant to their ability of trapping PARP1 on damaged DNA chains \[[@CR26]\]. This hypothesis is supported by the evidence that PARPis (e.g. Talazoparib) with stronger ability to trap PARP1 exhibit more potent cytotoxicity \[[@CR40]\]. The pharmacodynamics mechanism of PARP1 is similar to topoisomerase II inhibitor which could also trap damaging repair proteins on DNA chains and induce cell death \[[@CR40]\].Table 1Clinical PARP inhibitorsPARP inhibitorOlaparibRucaparibNiraparibTalazoparibVeliparibApprovalsOvarian cancerBreast cancerOvarian cancerOvarian cancerOvarian cancerNot approvedPARP trapping potencyMiddleMiddleMiddleHighLowRecommended dose300 mg BID600 mg BID300 mg BID1 mg QD600 mg BIDThe most common adverse reactions (in at least 20% patients)Anemia, nausea, fatigue, vomiting, nasopharyngitis, diarrhea, arthralgia/myalgia, dysgeusia, headache, dyspepsia, decreased appetite, constipation, and stomatitisNausea, fatigue, vomiting, anemia, abdominal pain, dysgeusia, constipation, decreased appetite, diarrhea, thrombocytopenia, and dyspneaNausea, thrombocytopenia, fatigue, anemia, constipation, vomiting, neutropenia, headache, decreased appetite, insomnia, abdominal painFatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhea, decreased appetiteNausea, fatigueData of Olaparib, Rucaparib, Niraparib, and Talazoparib are obtained from <https://www.fda.gov/>Data of Veliparib is obtained from NCT01149083

FDA-approved PARP inhibitors {#Sec4}
----------------------------

### Olaparib {#Sec5}

Olaparib capsule (Lynparza, AstraZeneca) is the first PARPi entering clinical practice. Olaparib was originally approved for deleterious or suspected deleterious gBRCAm ovarian cancer patients who had undergone three or more prior lines chemotherapy \[[@CR41]\]. Later in 2017, based on two randomized controlled trials (NCT01874353 and NCT00753545), Food and Drug Administration (FDA) approved Olaparib tablet for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer patients who were sensitive to platinum-based chemotherapy \[[@CR42], [@CR43]\]. Besides, the data of NCT01874353 supported the approval of Olaparib tablet for the maintenance treatment of gBRCAm or somatic BRCA-mutated (sBRCAm) recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer patients \[[@CR42]\]. Then in 2018, propelled by the encouraging results of the clinical trial NCT02000622, Olaparib tablet was approved by FDA for the treatment of human epidermal growth factor receptor-2 (Her-2) negative, metastatic breast cancer patients who had been treated with chemotherapy \[[@CR44]\]. Then in 2019, the results of a phase 3 trial (POLO study) showed that maintenance Olaparib treatment effectively prolonged the survival time of gBRCAm metastatic prostate cancer patients \[[@CR45]\]. In this study, totally 154 patients were enrolled and the primary end-point was progression-free survival (PFS) \[[@CR45]\]. Olaparib-treated patients had better outcomes than placebo-treated patients (the median PFS of Olaparib group vs. placebo group = 7.4 months vs. 3.8 months; Hazard Ration = 0.53; 95%CI 0.35 to 0.82; p = 0.004) \[[@CR45]\].

### Rucaparib {#Sec6}

The efficacy of Rucaparib (Rubraca, Clovis Oncology Inc.) was investigated in a randomized and double-blind phase 3 clinical trial NCT01968213. This trial enrolled 564 recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer patients who had received two or more prior lines of platinum-based chemotherapy and were sensitive to the platinum-based chemotherapy \[[@CR46]\]. The treatment effect was evaluated by PFS \[[@CR46]\]. The results indicated that Rucaparib could effectively improve the prognosis of BRCA1/2 mutated patients (Rucaparib group vs. placebo group: Hazard Ratio = 0.23, 95% CI 0.16--0.34, p \< 0.0001) \[[@CR46]\]. Besides, analysis in all population showed that patients received Rucaparib therapy had a great advantage in PFS over placebo-treated patients: Hazard Ratio = 0.36, 95% CI = 0.30--0.45; p \< 0.0001) \[[@CR46]\]. Based on the outcome of NCT01968213, FDA approved the maintenance treatment of Rucaparib for recurrent ovarian, fallopian tube, or primary peritoneal cancer patients who were sensitive to platinum-based chemotherapy in 2018 \[[@CR47]\].

### Niraparib {#Sec7}

Niraparib is developed by Tesaro which is also known as ZEJULA. In a randomized and double-blind phase 3 trial (NCT01847274), 553 platinum sensitive, recurrent ovarian cancer patients were involved \[[@CR48]\]. In gBRCAm cohort, patients receiving Niraparib had prolonged PFS than patients treated by placebo (median PFS of Niraparib group vs. placebo group = 21.0 vs. 5.5 months, Hazard Ratio = 0.27; 95% CI 0.17--0.41, p \< 0.001) \[[@CR48]\]. In non-gBRCAm cohort, Niraparib group also exhibited better prognosis than placebo group (median PFS of Niraparib group vs. placebo group = 9.3 vs. 3.9 months, Hazard Ratio = 0.45, 95% CI 0.34--0.61, p \< 0.001) \[[@CR48]\]. This promising results of NCT01847274 directly propelled the approval of Niraparib for the maintenance treatment of platinum sensitive, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer patients \[[@CR49]\].

### Talazoparib {#Sec8}

Among all available PARPis up to now, Talazoparib (TALZENNA, Pfizer Inc.) possesses the most PARP1 trapping and cytotoxic potency. The anti-tumor effect of Talazoparib has been verified in gBRCAm advanced breast cancer patients \[[@CR50]\]. This randomized and open-label phase 3 clinical trial (NCT01945775) recruited 431 patients \[[@CR50]\]. Compared with standard therapy group, Talazoparib group had significantly improved outcomes (median PFS of Talazoparib group vs. standard therapy group = 8.6 vs. 5.6 months, Hazard Ratio = 0.54, 95% CI 0.41--0.71, p \< 0.001) and better response rate (objective response rate of Talazoparib group vs. standard therapy group = 62.6% vs. 27.2%; Odds Ratio = 5.0; 95% CI 2.9--8.8, p \< 0.001) \[[@CR50]\]. Based on the data of NCT01945775, FDA approved Talazoparib for deleterious or suspected deleterious gBRCAm Her2‑negative, advanced breast cancer patients \[[@CR51]\].

PARP inhibitors in clinical trials {#Sec9}
----------------------------------

Until now, Veliparib has not been approved by FDA for cancer treatment. Multiple clinical studies indicated Veliparib-based combination therapy might be a promising strategy for triple negative breast cancer, ovarian cancer, pancreas ductal adenocarcinoma, myeloid leukemia, as well as hepatocellular carcinoma patients \[[@CR52]--[@CR56]\]. In a randomized, multicenter, phase 2 trial NCT01042379, total 116 stage II or III triple negative breast cancer patients received Veliparib combined Carboplatin therapy or Carboplatin monotherapy \[[@CR57]\]. The results of NCT01042379 showed Veliparib plus Carboplatin group had a higher response rate than Carboplatin group (pathological complete response rate of Veliparib plus Carboplatin group vs. Carboplatin group: 51% vs. 26%) \[[@CR57]\]. However, in a recent phase 3 trial NCT02032277 recruiting 634 stage II or III triple negative breast cancer patients, Veliparib plus Paclitaxel plus Carboplatin treated patients did not exhibit higher response rate than patients receiving Paclitaxel plus Carboplatin therapy (pathological complete response rate of Veliparib plus Paclitaxel plus Carboplatin group vs. Paclitaxel plus Carboplatin group: 53% vs. 58%, p = 0.36) \[[@CR58]\]. Therefore, further investigation is needed to confirm the optimal scheme and the population which might benefit from Veliparib-based combination therapy.

Application of PARPi beyond BRCA1/2 mutated cancer {#Sec10}
==================================================

HR deficient cancer {#Sec11}
-------------------

BRCAness tumors are not driven by gBRCAm but share certain phenotypes. In general, BRCAness tumors harbor non-gBRCAm HR deficiency including gBRCAm and hypermethylation of BRCA1/2 promotor \[[@CR59], [@CR60]\]. Besides, some other core components of HR such as RAD51 recombinase (RAD51), ATM serine/threonine kinase (ATM), ATR serine/threonine kinase (ATR), partner and localizer of BRCA2 (PALB2), and Fanconi anemia gene family are determinants of intact HR as well \[[@CR40], [@CR61]\]. Just like gBRCAm cancer cells, cancer cells with non-gBRCAm HR deficiency exhibited the sensitivity to platinum-based drugs and PARPis \[[@CR23], [@CR62]\]. However, the identification of HR deficiency in cancer cells is a complex work. Thus, it is necessary to find a measurable surrogate to evaluate HR status. It has been verified that gBRCAm patients often have a specific pattern of mutations including large scale chromosomal rearrangements which might reflect impaired HR potency and hyperactive NHEJ pathway \[[@CR59]\]. Some biomarkers such as loss of heterozygosity (LOH) closely relate with chromosomal rearrangements and predict favorable therapeutic response after PARPi treatment \[[@CR63]\].

Cancer with high replication stress {#Sec12}
-----------------------------------

Even though the synergistic effect caused by PARPi and HR deficiency has been confirmed in previous studies, some HR proficient cancers such as small cell lung cancer (SCLC) showed relatively high vulnerability to PARPi \[[@CR15]\]. This sensitivity is attributed to high replication stress driven by the loss of some tumor suppressor genes and the amplification of oncogenes \[[@CR15]\]. SCLC possesses a unique gene expression profile which is characterized as the ubiquitous loss of TP53 and RB1 \[[@CR64]\]. As well-studied tumor suppressor genes, TP53 and RB1 play a vital role in cell cycle checkpoint and DNA damage response \[[@CR64]\]. Besides, the loss of RB1 abrogates the E2F1-mediated transcription inhibition of multiple DNA damage response genes including PARP1 \[[@CR65]\]. Apart from the loss of TP53 and RB1, SCLC often harbors MYC amplification which further increases high replication stress \[[@CR15]\]. Compared with non-small cell lung cancer (NSCLC), SCLC is more dependent on hyperactive DNA damage response and more sensitive to PARPi treatment \[[@CR15]\].

PARPi-involved combination therapy {#Sec13}
==================================

In multiple PARPi-involved combination strategies, PARPi acts as sensitizers for chemotherapies, immunotherapies, and targeted therapies by limiting DNA damage repair. In addition, some targeted treatments such as MEK inhibitors could enhance the sensitivity of tumor cells and relieve the resistance to PARPi \[[@CR66]\].

PARPi plus genotoxic chemotherapy {#Sec14}
---------------------------------

Hyperactive PARP related DNA damage repair tends to result in the resistance to genotoxic chemotherapy such as Temozolomide (TMZ) and platinum compound (Table [2](#Tab2){ref-type="table"}) \[[@CR67]\]. Previous studies indicated that additional PARP inhibitor significantly decreased the risk of TMZ resistance and enhanced TMZ efficacy in mouse model \[[@CR68]--[@CR71]\]. These phenomena could be explained by mechanism that PARP-related DNA damage repair pathway especially BER could remove adducts from DNA chains and eliminate genotoxic chemotherapy-introduced DNA lesions \[[@CR67]\].Table 2Clinical trials about PARP inhibitor plus chemotherapyCombination therapyTrialCancerPhaseStatusRucaparib and CisplatinNCT01074970Breast cancer2Active, not recruitingOlaparib, Paclitaxel, and CarboplatinNCT03150576Breast cancer2/3RecruitingPF-01367338 and CarboplatinNCT01009190Advanced solid tumors1CompletedBSI-201 and IrinotecanNCT01173497Breast cancer2CompletedBSI-201, Carboplatin, and GemcitabineNCT00813956Breast cancer2CompletedVeliparib and Topotecan HydrochlorideNCT01012817Multiple solid tumors1/2Active, not recruitingOlaparib, Cediranib, and Platinum-based ChemotherapyNCT02855697Ovarian cancer1RecruitingOlaparib and Platinum agentsNCT02489006Ovarian cancer2RecruitingIniparib, Carboplatin, and GemcitabineNCT00540358Breast cancer2CompletedAZD2281 and Liposomal DoxorubicinNCT00628251Ovarian cancer2CompletedOlaparib, Temozolomide, and IrinotecanNCT01858168Ewing's sarcoma1RecruitingBMN-673, Temozolomide, and Irinotecan HydrochlorideNCT02049593Advanced solid tumors1Active, not recruitingAZD2281 and TopotecanNCT00516438Advanced solid tumors1CompletedAZD2281 and GemcitabineNCT00515866Pancreatic cancer1CompletedAZD2281 and DacarbazineNCT00516802Melanoma1CompletedVeliparib, VX-970, and CisplatinNCT02723864Advanced solid tumors1RecruitingNiraparib and TemozolomideNCT03830918Small cell lung cancer1/2RecruitingRucaparib and Platinum-based ChemotherapyNCT02855944Ovarian cancer3RecruitingBGB-290 and TemozolomideNCT03914742Gliomas1/2Not yet recruitingAZD2281, Carboplatin, and PaclitaxelNCT00516724Multiple solid tumors1Active, not recruitingTalazoparib, Irinotecan, and TemozolomideNCT02392793Childhood solid tumors1Active, not recruitingAZD2281, Cisplatin, and GemcitabineNCT00678132Solid tumor cancers1CompletedTalazoparib and TemozolomideNCT03672773Small cell lung cancer2RecruitingVeliparib and TemozolomideNCT01139970Acute leukemia1Active, not recruitingVeliparib and DoxorubicinNCT01145430Ovarian cancer1CompletedTalazoparib and DecitabineNCT02878785Acute leukemia1/2RecruitingOlaparib and TemozolomideNCT03880019Uterine leiomyosarcoma2Not yet recruitingBGB-290 and TemozolomideNCT03749187Gliomas1RecruitingVeliparib, Fluorouracil, and Irinotecan HydrochlorideNCT02890355Pancreatic cancer2Active, not recruitingOlaparib and TemozolomideNCT03212742Gliomas1/2RecruitingABT-888 and Topotecan HydrochlorideNCT00553189Solid tumors and lymphomas1CompletedOlaparib and TemozolomideNCT01390571Glioblastoma1CompletedIniparib, Gemcitabine, and CisplatinNCT01086254Non-small cell lung cancer2CompletedRucaparib, Docetaxel, and CarboplatinNCT03442556Prostate cancer2RecruitingVeliparib, Carboplatin, and PaclitaxelNCT00535119Advanced solid cancer1CompletedVeliparib, Carboplatin, Paclitaxel, and PemetrexedNCT02944396Non-small cell lung cancer1/2Active, not recruitingVeliparib and CyclophosphamideNCT01351909Breast cancer1Active, not recruitingABT-888 and TemozolomideNCT01009788Breast cancer2Active, not recruitingBSI-201, Gemcitabine, and CarboplatinNCT01045304Breast cancer2CompletedVeliparib and TemozolomideNCT03581292Glioma2RecruitingBSI-201, Gemcitabine, and CarboplatinNCT01213381Advanced solid tumors1CompletedOlaparib, Paclitaxel, Topotecan Hydrochloride, and DoxorubicinNCT02502266Ovarian cancer2/3RecruitingOlaparib and PaclitaxelNCT02789332Breast Cancer2RecruitingVeliparib, Carboplatin, Paclitaxel, and FOLFIRINCT02033551Solid Tumors1CompletedVeliparib, Carboplatin, Cisplatin, Fluorouracil, Hydroxyurea, and PaclitaxelNCT01711541Head and neck cancer1/2Active, not recruitingVeliparib, Gemcitabine, and CarboplatinNCT02860819Testicular germ cell cancer2RecruitingVeliparib, Carboplatin, and PaclitaxelNCT02264990Non-small cell lung cancer3Active, not recruitingVeliparib and CarboplatinNCT01149083Breast cancer2Active, not recruitingVeliparib and Mitomycin CNCT01017640Solid tumors1CompletedVeliparib, Paclitaxel, and CisplatinNCT01281852Cervical cancer1CompletedVeliparib, Paclitaxel, Carboplatin, and Bevacizumab,NCT00989651Ovarian cancer1Active, not recruitingABT-888 and TemozolomideNCT00994071Nervous system tumor1CompletedVeliparib and CisplatinNCT02595905Breast cancer2RecruitingVeliparib, Paclitaxel, and CarboplatinNCT01366144Solid tumors1SuspendedVeliparib, Gemcitabine Hydrochloride, and CisplatinNCT01585805Pancreatic cancer2Active, not recruitingVeliparib, Cyclophosphamide, and Doxorubicin HydrochlorideNCT00740805Solid tumors or non-hodgkin lymphoma1Active, not recruitingVeliparib, Topotecan Hydrochloride, and CarboplatinNCT00588991Acute leukemia, high-risk myelodysplasia, and myeloproliferative disorders1Active, not recruitingVeliparib, Bendamustine Hydrochloride, and RituximabNCT01326702Lymphoma, multiple myeloma, solid tumors1/2CompletedVeliparib, Cisplatin, and Vinorelbine DitartrateNCT01104259Breast cancer1CompletedThe details of the table are obtained from <https://www.clinicaltrials.gov/>

### PARPi plus TMZ {#Sec15}

As a widely adopted DNA-alkylating agent, TMZ could spontaneously hydrolyze and release reactive methyldiazonium ion which eventually leads to the production of DNA adducts \[[@CR72]\]. PARPi is regard as an effective sensitizer for TMZ by counteracting the PARP-BER-mediated detoxification \[[@CR73]\]. Hussain et al. conducted a single-arm phase 1 trial (NCT01085422) to evaluate the safety and efficacy of low dose Veliparib plus TMZ combination therapy in metastatic castration-resistant prostate cancer patients \[[@CR74]\]. The results showed this combination therapy was well-tolerant while its anti-cancer effect was relative modest (Just 3 out of 25 patients showed confirmed PSA response) \[[@CR74]\]. Nevertheless, more clinical trials exploring the effect of PARPi and TMZ are ongoing \[[@CR75]\].

### PARPi plus platinum {#Sec16}

Similar to TMZ, platinum compounds could also generate adducts to DNA chains which leads to the formation of stable intra-strand cross-links \[[@CR76]\]. As a result, the replication and transcription processes in treated cells are severely interfered. Platinum resistance is closely related with DNA damage repair and could be overcome by PARPi \[[@CR77]\]. In preclinical experiment, Olaparib and Veliparib remarkably potentiated cisplatin-induced cytotoxicity \[[@CR78]\]. Later, a phase 2 study (NCT01081951) assessed the efficacy of the combination therapy of Olaparib plus platinum-based chemotherapy in platinum-sensitive, recurrent ovarian cancer patients \[[@CR79], [@CR80]\]. The results demonstrated that patients receiving Olaparib plus platinum-based chemotherapy had markedly better outcomes than chemotherapy treated patients (median overall survival of Olaparib plus platinum-based chemotherapy group vs. chemotherapy group: 12.2 vs 9.6 months, Hazard Ratio = 0.51, 95% CI 0.34--0.77, p = 0.0012) \[[@CR79]\]. In 2018, Loibl et al. reported the results of phase 3 trial (NCT02032277) which evaluated the efficacy of Veliparib plus carboplatin plus paclitaxel combination therapy in triple-negative breast cancer patients \[[@CR58]\]. Patients undergoing concurrent Veliparib plus carboplatin plus paclitaxel had a significantly increased response rate than paclitaxel-treated patients (53% vs. 31%, p \< 0.0001) \[[@CR58]\].

PARPi plus immune checkpoint inhibitor {#Sec17}
--------------------------------------

As the crucial co-inhibitory molecules regulating immune activation and tolerance, programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) induce dephosphorylation via intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM) \[[@CR81]--[@CR83]\]. T cell receptor (TCR) mediated tyrosine phosphorylation and T cell activation are undermined \[[@CR84]\]. In tumor microenvironment, the expression of PD-L1 is usually upregulated which increases the ratio of exhausted T cells and interferes robust immune surveillance \[[@CR85]\]. Immune checkpoint inhibitors (ICI) restore T cell from exhausted status and stimulate anti-cancer immune response \[[@CR86]\]. However, the clinical application of ICI is limited by low response rate which is related with tumor mutation burden and the status of tumor infiltrating lymphocytes (TILs) \[[@CR87], [@CR88]\].

PARPi therapy has a substantial influence on systemic immune response \[[@CR89]\]. On the one hand, PARPi introduces large scale chromosome recombination which might generate quantities of neoantigen and increase the immunogenicity of cancers \[[@CR40]\]. On the other hand, PARPi-induced DSB could be detected by cytosolic DNA sensor and activates the downstream cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING)-type-I interferon (IFN) pathway \[[@CR90]\]. Type I IFN is a versatile molecule which promotes the cross-presentation of dendritic cell (DC), enhances the trafficking and migration of T cells, as well as induces the secretion of Th1-skewing cytokines \[[@CR91], [@CR92]\]. Compared with low level inflammation in baseline, PARPi treatment leads to catastrophic DNA damage and acute inflammation \[[@CR89]\]. This PARPi-introduced transformation of microenvironment facilitates immune priming and activation \[[@CR89]\]. In mouse model bearing SCLC, combination therapy of Olaparib and anti-PD-L1 showed more potent anti-cancer effect than monotherapy and induced complete tumor regression in all treated mice \[[@CR90]\]. Immune profiling of resected tumors indicated that the combination therapy significantly elevated the abundance of tumor infiltrating CD3^+^ T cells and CD8^+^ cytotoxic T cells \[[@CR90]\]. Moreover, the synergistic effect between PARPi and ICI was confirmed in multiple mice cancer models including breast cancer, ovarian carcinoma, and skin tumor \[[@CR93], [@CR94]\]. Accumulating evidence demonstrated that PARPi could promote anti-cancer immune response while anti-PD-1/PD-L1 could neutralize PARPi-induced PD-L1 upregulation \[[@CR89]\].

In 2018, Karzai et al. reported the results of phase 2 clinical trial NCT02484404. 17 metastatic castration-resistant prostate cancer patients were enrolled into this study and received Olaparib plus Durvalumab treatment \[[@CR95]\]. The results showed that the toxicity of combination therapy was acceptable (grade 3/4 adverse event occurred in 2/17 patients) and the efficacy of combination therapy was satisfactory especially in DNA damage repair deficient patients (median PFS: 16.1 months, 95% CI 7.8--18.1 months) \[[@CR95]\]. The efficacy of combination scheme of Olaparib plus Durvalumab was also evaluated in relapsed SCLC patients \[[@CR96]\]. The results of SCLC cohort of NCT02484404 showed that the response rate of overall SCLC patients was relative low (Ration of patients with confirmed responses or prolonged stable disease: 21.1%; 95% CI 6.1--45.6%), but all patients with tumors classified as inflamed phenotype exhibited positive therapeutic response \[[@CR96]\].

PARPi plus targeted therapy {#Sec18}
---------------------------

Acquired resistance to PARPi is an important obstacle which has not been well resolved. Factors such as secondary reversion BRCA1/2 mutation, loss of PAPR1, as well as restoration of HR are related to PARPi resistance. Oncogene-related signaling pathways such as androgen receptor (AR), mitogen-activated protein kinase (MEK), BET bromodomain (BRD4) pathways could directly drive the expression of HR related proteins and induce PARPi resistance \[[@CR15]\].

### PARPi plus AR inhibitor {#Sec19}

Asim et al. found that intact AR signaling was indispensable to maintain the expression and activity of HR related genes in prostate cancer cells \[[@CR97]\]. After androgen-deprivation therapy, the activity of HR was impaired and prostate cancer cell was highly dependent on PARP-BER pathway to repair DNA damages \[[@CR97]\]. This artificially induced BRCAness phenotype endows the sensitivity to PARPi treatment in prostate cancer cells \[[@CR98]\]. In 2018, a phase 2 trial (NCT01972217) confirmed the efficacy of double blockade of AR and PARP in metastatic, castration resistant prostate cancer patients \[[@CR99]\]. Patients receiving Olaparib plus Abiraterone therapy had better survival data than patients treated with Abiraterone therapy (median radiographic PFS of Olaparib plus Abiraterone group vs. Abiraterone group: 3.8 vs. 8.2 months, Hazard ratio = 0.65, 95% CI 0.44--0.97, p = 0.034) \[[@CR99]\].

### PARPi plus MEK inhibitor {#Sec20}

Sun et al. found that MEK inhibitor could increase the sensitivity to PARPi treatment in RAS mutated ovarian cancer patients by inhibiting HR repair activity and elevating PARP expression \[[@CR100]\]. Besides, PARPi plus MEK inhibitor therapy induced cell apoptosis by activating BIM signaling \[[@CR100]\]. This MEK inhibitor-based combination therapy showed potent anti-cancer effect in multiple cancer cell lines and mice models not limited to BRCA1/2 mutated cells \[[@CR100]\]. The results of in vivo and in vitro experiments showed that the combination strategy is a promising manner to overcome PARPi resistance and increase the response intensity, duration, and spectrum of PARPi.

### PARPi plus BRD4 inhibitor {#Sec21}

BRD4 promotes cancer cell proliferation and survival by maintaining and facilitating oncogenic transcription \[[@CR101]\]. The expression of BRD4 is often upregulated and predicts poor prognosis in high-grade serous ovarian carcinoma patients \[[@CR102]\]. Sun et al. found that BRD4 bound to the promoter and enhancer of C-terminal binding protein interacting protein (CtIP) which was the core component of HR pathway \[[@CR103]\]. BRD4 inhibitor suppressed the expression of CtIP and interfered the recruitment of DNA damage repair proteins to DNA lesions \[[@CR103]\]. In vitro experiments, BRD4 inhibitor treatment restored the sensitivity of to PARPi therapy in PARPi-resistant cells \[[@CR103]\]. In vivo experiment, the combination therapy of PARPi and BRD4 inhibitor effectively prolonged tumor control in multiple patient-derived tumor xenograft models including HR proficient ovarian and breast cancers \[[@CR103]\].

Conclusion {#Sec22}
==========

Synthetic lethal interaction is context-dependent where the alteration in first gene leads to the essential role of second gene for the viability of cancer cells. Targeting the product of second gene could selectively kill malignant cells with minor effect on nonmalignant cells. Since synthetic lethal effect was proposed nearly 100 years ago, this hypothesis has been intensively studied. PARPi is the first agent based on synthetic lethal concept. The great success of PARPi in preclinical and clinical studies propels the approval of four PARPis for BRCA1/2 mutated ovarian and breast cancer patients. However, data of some clinical trials showed that a broader range of populations might benefit from PARPi. Establishing a comprehensive evaluation framework to select candidates for PARPi treatment is necessary. Besides, combination therapy with additional ICI, HR targeting agents, as well as chemotherapy have shown synergistic effect even in PARPi resistant models. Accumulating evidence in preclinical studies indicates PARPi is a promising therapy cross multiple cancer types. We believe the future clinical studies would provide more novel perspectives for optimal PARPi-based combination scheme.

SSB

:   DNA single-strand break

DSB

:   double-strand break

MMR

:   mismatch repair

NER

:   nucleotide excision repair

BER

:   base excision repair

HR

:   homologous recombination

NHEJ

:   nonhomologous end joining

PARP

:   Poly (ADP-ribose) polymerase

gBRCAm

:   germline BRCA1/2 mutated

HD

:   helical domain

ART

:   ADP-ribosyltransferase catalytic domain

β-NAD

:   β-nicotinamide adenine dinucleotide

FDA

:   Food and Drug Administration

sBRCAm

:   somatic BRCA-mutated

PFS

:   progression-free survival

LOH

:   loss of heterozygosity

SCLC

:   small cell lung cancer

NSCLC

:   non-small cell lung cancer

TMZ

:   Temozolomide

PD-1

:   programmed cell death-1

CTLA-4

:   cytotoxic T-lymphocyte-associated protein 4

ITIM

:   intracellular immunoreceptor tyrosine-based inhibitory motif

TCR

:   T cell receptor

ICI

:   immune checkpoint inhibitors

TIL

:   tumor infiltrating lymphocyte

cGAS

:   cyclic GMP-AMP synthase

STING

:   stimulator of interferon genes

IFN

:   interferon

DC

:   dendritic cell

AR

:   androgen receptor

MEK

:   mitogen-activated protein kinase

BRD4

:   BET bromodomain

CtIP C

:   C-terminal binding protein interacting protein
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